Kornimate/medical-research-clean huggingface dataset:
endometrioma treatment and ovarian function

Conditions: Endometrioma

Summary: ovarian endometriosis (endometrioma) can be a cause of subfertility. according to european society of human reproduction and embryology (eshre) guidelines, surgery for endometrioma is recommended when an endometrioma is more than 3 cm in diameter because this management is associated with better spontaneous conception rates. nevertheless, surgery can also be potentially associated with a risk of destruction of functional ovarian tissue and reduction in ovarian reserve. anti-müllerian hormone (amh) is a member of the transforming growth factor beta family and is expressed by the small (\<8 mm) pre-antral and early antral follicles. the amh level reflects the size of the primordial follicle pool, and may be the best biochemical marker of ovarian function across an array of clinical situations its level in serum is almost stable between 20 and 35 years of the woman´s life, unless using hormonal contraception and / or they suffer with polycystic ovarian syndrome (pcos). the level of amh is also a useful indicator for the prediction chances of success of spontaneous or assisted conceptions. however, there paucity of data regarding changes in serum levels of amh following surgery for endometrioma. an alternative way for estimating ovarian reserve is quantifying ovarian mass with using standard 3d transvaginal ultrasound calculation (ovm) and assessment of antral follicular count. the gold standard of endometrioma surgery is laparoscopic excision with suture or gentle coagulation of the rest of ovary or by the use of laparoscopic treatment with argon plasma energy.


Eligibility criteria:
inclusion criteria: * women with endometrioma 3cm and more in diameter exclusion criteria: * using hormonal contraception or other hormonal treatment last 6 months * suffer with polycystic ovarian syndrome

Keywords: endometrioma amh
personalized insemination treatment study

Conditions: Infertility; Intrauterine Insemination; Reproduction

Summary: this study is intended for women undergoing their first cycle of 3 intrauterine inseminations. all 3 inseminations will be personalized by using algorithms to determine the dose of study medication.

study medication dosage for the first insemination cycle will be based on the woman's age as well as her anti-mullerian hormone (amh) levels. study medication dosage for the second and third insemination will depend on ovarian response (number of follicles) during previous insemination cycle and woman's age

Eligibility criteria:
inclusion criteria: * women having consented to the study * women followed at fertility center * first iui cycle * women between the ages of 18 to 42 inclusively at time of consent form signature * amh \< 35 pmol/l (4.9 ng/ml) in participants' file in the last 24 months * at least one permeable fallopian tube confirmed by laparoscopy, hysterosalpingography (hsg), hysterosalpingosonography (hssg) or one pregnancy in the last 3 years * insemination with either partner or donor sperm * male partner semen analysis considered adequate for iui in accordance to the centre's standard practice * menstrual cycles from 26 to 39 days * presence of both ovaries exclusion criteria: * unable to consent * body weight \>100 kg * amh ≥35 pmol/l (4.9 ng/ml) in participants' file in the last 24 months * severe malformation (unicornuate or bicornuate uterus) or uterine anomaly including fibroids ≥ 5 cm * uncontrolled thyroid or adrenal dysfunction * pituitary tumour * persistent ovarian cysts or enlargement not due to pcos (polycystic ovary syndrome) \> 3 cm * anovulatory women * use of contraceptives in the last 3 months prior to start of stimulation * diagnosis of hydrosalpinx * malignancies * breast pathology incompatible with gonadotropin stimulation * hypersensitivity to follitropin delta or to any ingredient in the formulation * addition of other infertility medication that can influence follicle stimulation and maturation such as growth hormone (gh)
the long-term value of preoperative duplex before surgery for varicose veins

Conditions: Varicose Veins

Summary: duplex imaging is costly and time-consuming, but is used increasingly for preoperative evaluation of varicose veins. its value in terms of the long-term results of surgery is not clear. 293 patients (343 limbs) with primary varicose veins were randomized to operation with or without preoperative duplex imaging. reoperation rates, clinical and duplex findings were compared at 2 months and 2 years after surgery. routine preoperative duplex examination led to an improvement in results. however two years is a short time, and with a longer follow-up other mechanisms for recurrence may become more important, e.g. neovascularization (new vessel formation) or progression of disease, hence the value of a detailed preoperative diagnosis may be diminished. the aim of this phase of the investigation is to study the results after 8 years, in particular what mechanisms for recurrences were most important.


Eligibility criteria:
inclusion criteria: * patients with primary varicose veins exclusion criteria: * pure cosmetic complaints * previous venous surgery or sclerotherapy * history of suspect or manifest deep venous thrombosis * active or healed venous ulceration * peripheral arterial disease * previous significant trauma to the leg * general illness * alcohol or drug abuse * unable to understand information

Keywords: varicose veins venous insufficiency surgery duplex recurrence
methylphenidate and parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this trial is to determine if methylphenidate (mpd), a drug marketed in the u.s. to treat hyperactivity and narcolepsy, added to levodopa, will increase the beneficial effects of levodopa without bothersome side effects in people with parkinson's disease (pd).

parkinson's disease (pd) is a common disorder caused by the loss of dopamine-producing brain cells. the disorder is generally treated with levodopa combined with carbidopa. nerve cells use levodopa to make dopamine. carbidopa delays the conversion of levodopa into dopamine until it reaches the brain. motor fluctuations (the wearing off effects of levodopa characterized by sometimes rapid changes between uncontrolled and normal movements) are a common, and often difficult to manage, source of disability in people with pd. in this trial researchers will study the effects of methylphenidate (mpd), also known as ritalin-a drug marketed in the u.s. to treat hyperactivity and narcolepsy-on carbidopa/levodopa and other antiparkinson medications taken orally by individuals with parkinson's disease who experience motor fluctuations when they take levodopa. the overall goal of this project is to develop better symptomatic therapies for pd. after 2 screening visits to the treatment clinic to evaluate the wearing "on" and "off" effects of levodopa, eligible participants will be scheduled for 3 admissions to the general clinical research center at oregon health \& science university during which they randomly will receive the study drug, mpd, or placebo, along with their usual carbidopa/levodopa therapy and/or other antiparkinson medications. also, participants will have their parkinsonism (tremor, rigidity, postural instability, and bradykinesia) rated and blood pressure and pulse measured at regular intervals. duration of the study for participants is about 3 weeks and includes 2 outpatient clinic visits (for screening) and 3 inpatient clinic visits (with overnight stays).

Eligibility criteria:
inclusion criteria: * idiopathic pd treated with levodopa and experiencing motor fluctuations * at least 21 years of age * male or female. exclusion criteria: * cardiovascular disease, psychosis, extreme anxiety, dementia and other unstable medical conditions.

Keywords: parkinson's disease pd methylphenidate ritalin mpd
diagnosis and treatment of patients with cystic fibrosis

Conditions: Cystic Fibrosis; Liver Disease or Abnormalities; Diabetes; Pancreatic Insufficiency (Exocrine and Endocrine)

Summary: this is an omnibus protocol for studying patients with cystic fibrosis. the main purpose of the study is to obtain samples and data collected during standard clinical care for future research to expand knowledge of the natural history, clinical manifestations (phenotypes) and the genetic variants (genotypes) of cystic fibrosis.

this is an omnibus protocol for studying patients with cystic fibrosis. the main purpose of the study is to obtain samples and data collected during standard clinical care for future research to expand knowledge of the natural history, clinical manifestations (phenotypes) and the genetic variants (genotypes) of cystic fibrosis.

Eligibility criteria:
* inclusion criteria * patients with known or suspected cf and family members of patients with cf. * \>=4 years of age exclusion criteria -concomitant medical, psychiatric or other problems which might complicate interpretation of studies of cf, or for which we are unable to provide adequate care.

Keywords: cystic fibrosis pancreatic insufficiency bronchiectasis liver disease natural history
regulatory hycamtin(oral) pms

Conditions: Lung Cancer, Small Cell

Summary: non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of topotecan administered in korean patients according to the prescribing information

non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of topotecan administered in korean patients according to the prescribing information topotecan will be administered as described the prescribing information or by physician's decision.

Eligibility criteria:
all subjects must satisfy the following criteria. * subject who is under the indication to the prescribing information of oral hycamtin. * subject who is treated with oral hycamtin according to the judgement of her or his investigator. all subjects must not satisfy the following criteria. • subject who is under the contraindication to the prescribing information of oral hycamtin. as considering the characteristic of observational post marketing surveillance, the exclusion criteria is not strict. all investigators should prescribe oral hycamtin according to prescribing information which approved in korea.

Keywords: pms (post-marketing surveillance) topotecan
evidence-based stimulation trial with human rfsh in europe and rest of world 2

Conditions: Infertility

Summary: this trial investigates the immunogenicity of fe 999049 in repeated cycles.


Eligibility criteria:
inclusion criteria: * informed consent documents signed prior to screening evaluations related to this protocol * participation in the pivotal efficacy trial (trial 000004/esther-1) * anti-fsh antibody results from baseline and at least one post-dosing assessment in the previous cycle(s) available. * having undergone the oocyte retrieval procedure, or having had cycle cancellation prior to oocyte retrieval due to poor ovarian response or excessive ovarian response, in the previous cycle(s). * failure to achieve ongoing pregnancy in the previous cycle(s). exclusion criteria: * non-compliance to protocol compliance in the previous cycle(s). * having undergone any stimulation with gonadotropins since the end-of-trial / end-of-cycle visit in the previous cycle * one or more follicles ≥10 mm observed on the transvaginal ultrasound prior to start of dosing on stimulation day 1 * severe ohss in a previous cycle. * any clinically relevant change to any of the eligibility criteria in the previous cycle(s). * clinically relevant medical history since the previous cycle which precludes gonadotropin stimulation or is associated with a reduced chance of pregnancy.
antireflux mucosectomy (arms) for treatment of gastroesophageal reflux

Conditions: Gastro Esophageal Reflux

Summary: this is a phase ii clinical study to investigate the safety and efficacy of endoscopic antireflux mucosectomy (arms) for treatment of gerd.

the objective of the study is to establish the clinical efficacy and safety of arms for treatment of gerd.

Eligibility criteria:
inclusion criteria: 1. patients with typical symptoms of gerd with symptomatic response to ppi therapy for ≥ 3 months 2. hill's grade ii and iii of the gastroesophageal junction 3. one of the following abnormalities in the objective assessment 3.1. excessive acid exposure at the distal esophagus evidenced by 24 hour ph tests using % total time ph \< 4 and / or demeester score 3.2. endoscopic evidence of la classes a,b,c or d esophagitis 3.3. defective les assessed by hrm with resting pressure of \< 6mmhg or total length of less than 4cm or abdominal length of less than 2cm exclusion criteria: 1. age \> 70 yrs of \< 18 yrs 2. pregnancy 3. any type of hiatus hernia 4. patients with underlying malignancy 5. asa above grade iii

Keywords: antireflux mucosectomy gerd
effect of some drugs on rheumatoid arithritis activity

Conditions: Rheumatoid Arthritis

Summary: effect of some drugs on rheumatoid arithritis activity.

the study aims at evaluating the effect of some drugs on rheumatoid arithritis activity.

Eligibility criteria:
inclusion criteria: * rheumatoid arthritis exclusion criteria: * liver or renal disease
selective rather than routine histopathological examination following appendectomy and cholecystectomy

Conditions: Appendix; Appendectomy; Appendiceal Neoplasms; Gallbladder; Cholecystectomy; Gallbladder Neoplasms

Summary: the fancy study will investigate whether a selective policy of histopathological examination of appendices and gallbladders based on the intraoperative findings of the surgeon is safe and cost-effective.

traditionally, all surgically removed appendices and gallbladders are sent to the department of pathology for histopathological examination. this is most likely not necessary in appendices and gallbladders that are not suspicious for a tumour when inspected visually or by palpation. if not detected by visual inspection or palpation, the tumour is usually of early stage and already treated with the resection of the organ. a policy of selective histopathological examination based on the intraoperative findings of the surgeon can probably reduce the amount of appendices and gallbladders that have to be examined by the pathologist, without a risk of undertreatment, with less risk of overtreatment and huge savings annually. in the fancy study, a nationwide prospective multicenter observational cohort study, all appendices and gallbladders will be evaluated for tumours by visual inspection and palpation by the operating surgeon. the operating surgeon will report his or her findings and also write down whether he or she thinks there is an indication for histopathological examination. subsequently, all specimens are sent to the pathologist for histopathological examination. therefore, no aberrant findings will be missed due to this study. the prospective cohort can be compared through modelling to a hypothetical situation where appendices and gallbladders are only examined by the pathologist on indication. the primary outcome is the number of patients per 1000 examined appendices/gallbladders with a neoplasm requiring additional therapy benefitting the patient that would have been unnoticed in the policy of selective histopathological examination.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo an appendectomy or cholecystectomy in the elective or non-elective setting. exclusion criteria: * primary indication for surgery: strong suspicion or proven malignancy in the appendix or gallbladder. * appendix or gallbladder removed as part of more extensive surgery, so-called incidental appendectomies or cholecystectomies. * patients included in the accure trial (effect of appendectomy on ulcerative colitis). * the presence of a gallbladder polyp of \>10 mm on preoperative imaging.

Keywords: appendix appendectomy gallbladder cholecystectomy neoplasms pathology selective routine
non-motor features of cervical dystonia (cd)

Conditions: Cervical Dystonia; Movement Disorders; Focal Dystonia; Signs and Symptoms; Nervous System Diseases; Neurologic Manifestations; Neuromuscular Manifestations; Spasmodic Torticollis

Summary: this study will examine the prevalence of four previously identified non-motor markers in a population of cervical dystonia patients, unaffected family members, and healthy volunteers in an attempt to identify a distinct combination of non-motor symptoms that may be indicative of disease development.

the primary aim of this study is to identify the prevalence of four previously identified non-motor markers - (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia - in a population of cervical dystonia patients, unaffected family members, and healthy volunteers (control group). consenting participants will receive a neurological examination performed by a movement disorders neurologist, followed by an assessment of the four non-motor symptoms. the investigators hypothesize that a distinct combination of non-motor symptoms will be more prevalent in the cd group, and therefore this set of symptoms may be indicative of disease development. this combination will be identified through analysis of the concurrence of the non-motor features across the three groups of participants. this study will fill an important unmet need, as to the investigators' knowledge there are no published studies assessing the comorbid presentation of these four non-motor symptoms in a single cervical dystonia population. the exploration of a distinct combination of concurrent non-motor symptoms as a marker for the development of cervical dystonia will improve the ability of movement disorders neurologists to diagnose the condition. the results of this study will facilitate the investigators' longstanding aim of improving rates of cervical dystonia diagnosis. cervical dystonia is currently diagnosed based upon the exclusion of other movement disorders; therefore, characterization of non-motor features in cervical dystonia patients will help to refine the diagnostic criteria for this condition. this investigation will also improve understanding of the factors associated with cd. future studies can examine the source of these associated factors in order to help understand the cause of cd, since the etiology is currently unknown.

Eligibility criteria:
inclusion criteria: * have a diagnosis of cervical dystonia, or a first order relation of a vanderbilt patient diagnosed with cervical dystonia, or a healthy volunteer who is neurologically normal * capable of participating in all study procedures * willing and able to provide written or verbal informed consent. exclusion criteria: * subjects for whom participation in the study may cause medical harm * subjects who are not considered competent to make their own medical decisions * subjects who display sensory deficits during a short screening examination prior to study enrollment
ocustem nutritional supplement in diabetic patients with mild to moderate non-proliferative retinopathy

Conditions: Diabetic Retinopathy

Summary: the purpose of this study is to determine whether supplementation with ocustem, a nutritional supplement, will reduce the progression of mild to moderate diabetic retinopathy.

this research study is designed to evaluate the effects of a nutritional supplement, ocustem, on mild to moderate nonproliferative diabetic retinopathy. in this condition blood vessels in the back of the eye, an area termed the retina, are deteriorating. ocustem contains ingredients that have previously been demonstrated in clinical trials to stimulate a type of cell, called "endothelial progenitor cells" to increase in circulation. animal studies have shown that increasing endothelial progenitor cell numbers inhibits progression of diabetic retinopathy. the hypothesis of the study is that a 6 month course of ocustem will reduce progression of mild to moderate diabetic retinopathy.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * one or both study eyes per subject may be enrolled. * diagnosis of diabetes mellitus (type 1 or type 2) * any one of the following will be considered to be sufficient evidence that diabetes is present: 1. current regular use of insulin for the treatment of diabetes 2. current regular use of oral anti-hyperglycemia agents for the treatment of diabetes 3. documented diabetes by ada and/or who criteria. * the study eye must meet the following: 1. presence of microaneurysms or at least mild non-proliferative diabetic retinopathy (level 20 or higher) on clinical exam. 2. no presence of center-involved diabetic macular edema (dme) as evidenced by oct central subfield thickness \<250 microns(or spectral domain oct equivalent). 3. visual acuity light perception or better. exclusion criteria: * a current ocular condition that, in the opinion of the investigator, visual acuity might be affected now and/or may need to be treated (e.g., dme, foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition (cataract ), epiretinal membrane or vitro-macular traction) or during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.). * a history of a major ocular surgery (including vitrectomy, scleral buckle, any intraocular surgery, etc.) within prior 4 months or major ocular surgery including cataract removal anticipated within the next 4 months following enrollment. * pregnant women
spinal fentanyl or epidural analgesia in the early first phase of induced labor

Conditions: Labor Pain; Induced; Birth

Summary: a total of 60 parturients undergoing induction of labour will be consented to participate in the study where they will be randomized to receive either spinal fentanyl (20 µg) or epidural analgesia (fentanyl 100µg and lidocaine 80 mg). they will be monitored for the development of analgesia for a duration of 30 minutes.


Eligibility criteria:
inclusion criteria: 1. signs a consent form to participate voluntarily into the trial 2. induced labor 3. singleton pregnancy 4. primiparous 5. bmi 20-40 at the time of delivery 6. no history of allergy for lidocaine or fentanyl 7. sufficient command of finnish language to understand the consent form and interview 8. cervical dilatation at maximum 4 cm at the time of intervention exclusion criteria: 1. any contraindication for spinal or epidural analgesia 2. allergy for lidocaine or fentanyl 3. the patient has received any opioid medication within 90 minutes prior to intervention

Keywords: epidural analgesia spinal analgesia labor pain